Heart transplant is the gold standard option for heart failure (HF) patients when all other options fail, says a cardiologist and heart failure specialist at the recent APSC 2017 Congress, with excellent long-term outcomes.
Lower total cholesterol-to-high density lipoprotein cholesterol ratio (TC:HDL) and low-density lipoprotein (LDL) levels appear to be associated with elevated mortality rates in patients with acute coronary syndrome (ACS), according to a study presented at the 21st Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Nonvitamin K antagonist (non-VKA) oral anticoagulants (NOACs) offer better outcomes than VKAs in Asian patients for the prevention of atrial fibrillation (AF)-associated stroke, according to data presented at the Asian Pacific Society of Cardiology Congress (APSC) 2017 held in Singapore.
Short-term use (<30 days) of the anticoagulant warfarin following bioprosthetic aortic valve replacement (AVR) reduced the incidence of major adverse cardiovascular events (MACE) but not the risk of bleeding and re-operation, while long-term warfarin use (31–90 days) resulted in a higher incidence of MACE and reoperation, according to data presented at the Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Reduction of resting heart rate (RHR) with the beta-blocker (β-blocker) bisoprolol was associated with a decreased incidence of composite cardiovascular (CV) events in Chinese patients with coronary artery disease (CAD) according to a study presented at the Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Remodeling of the left atrium continues into middle and old age as a form of haemodynamic compensation for alterations in the structure and function of the heart, according to a study presented at the recently concluded 21st Asian Pacific Society of Cardiology Congress (APSC 2017).
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.